The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant attention within the United Kingdom , prompting a notable shift in peptide trends. Access these compounds remains a complex challenge , with public healthcare system provision currently limited and specialist practices offering treatment at a high